.

Pharmaceutical Business Intelligence

  • Predict branded drug patent expiration
  • Formulary management
  • Obtain formulation and manufacturing information

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

PRANDIN Drug Profile

« Back to Dashboard

Which patents cover Prandin, and what substitute generic drugs are available?

Prandin is a drug marketed by Gemini Labs Llc and is included in one NDA.

The generic ingredient in PRANDIN is repaglinide. There are sixteen drug master file entries for this compound. Seventeen suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the repaglinide profile page.

Summary for Tradename: PRANDIN

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list5
Bulk Api Vendors: see list66
Patent Applications: see list6,114
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:PRANDIN at DailyMed

Pharmacology for Tradename: PRANDIN

Drug ClassGlinide
Mechanism of ActionPotassium Channel Antagonists
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gemini Labs Llc
PRANDIN
repaglinide
TABLET;ORAL020741-001Dec 22, 1997RXYesNo► Subscribe► Subscribe
Gemini Labs Llc
PRANDIN
repaglinide
TABLET;ORAL020741-002Dec 22, 1997RXYesNo► Subscribe► Subscribe
Gemini Labs Llc
PRANDIN
repaglinide
TABLET;ORAL020741-003Dec 22, 1997RXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: PRANDIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gemini Labs Llc
PRANDIN
repaglinide
TABLET;ORAL020741-002Dec 22, 19975,216,007► Subscribe
Gemini Labs Llc
PRANDIN
repaglinide
TABLET;ORAL020741-003Dec 22, 19975,216,167► Subscribe
Gemini Labs Llc
PRANDIN
repaglinide
TABLET;ORAL020741-001Dec 22, 19974,873,080► Subscribe
Gemini Labs Llc
PRANDIN
repaglinide
TABLET;ORAL020741-002Dec 22, 1997RE37035► Subscribe
Gemini Labs Llc
PRANDIN
repaglinide
TABLET;ORAL020741-003Dec 22, 19975,312,924► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: PRANDIN

Drugname Dosage Strength RLD Submissiondate
repaglinideTablets0.5 mg, 1 mg and 2 mgPrandin2/10/2005
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc